Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets
Abstract The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector–based vaccines significantly influences...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-022-00567-w |
| _version_ | 1827609944103321600 |
|---|---|
| author | Selina Khan Nadine C. Salisch Ana Izquierdo Gil Satish Boedhoe Karin Feddes-de Boer Jan Serroyen Hanneke Schuitemaker Roland C. Zahn |
| author_facet | Selina Khan Nadine C. Salisch Ana Izquierdo Gil Satish Boedhoe Karin Feddes-de Boer Jan Serroyen Hanneke Schuitemaker Roland C. Zahn |
| author_sort | Selina Khan |
| collection | DOAJ |
| description | Abstract The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector–based vaccines significantly influences antigen-specific immune responses induced by a subsequent vaccination with Ad26 vector–based vaccine regimens against different disease targets in non-human primates. A homologous Ad26 vector–based vaccination regimen or heterologous regimens (Ad26/Ad35 or Ad26/Modified Vaccinia Ankara [MVA]) induced target pathogen–specific immunity in animals, but also persistent neutralizing antibodies and T-cell responses against the vectors. However, subsequent vaccination (interval, 26–57 weeks) with homologous and heterologous Ad26 vector–based vaccine regimens encoding different target pathogen immunogens did not reveal consistent differences in humoral or cellular immune responses against the target pathogen, as compared to responses in naïve animals. These results support the sequential use of Ad26 vector–based vaccine regimens targeting different diseases. |
| first_indexed | 2024-03-09T07:40:41Z |
| format | Article |
| id | doaj.art-d491b13699db469ebcfbd2dc8b441508 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-09T07:40:41Z |
| publishDate | 2022-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-d491b13699db469ebcfbd2dc8b4415082023-12-03T04:48:15ZengNature Portfolionpj Vaccines2059-01052022-11-017111310.1038/s41541-022-00567-wSequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targetsSelina Khan0Nadine C. Salisch1Ana Izquierdo Gil2Satish Boedhoe3Karin Feddes-de Boer4Jan Serroyen5Hanneke Schuitemaker6Roland C. Zahn7Janssen Vaccines & PreventionJanssen Vaccines & PreventionJanssen Vaccines & PreventionJanssen Vaccines & PreventionJanssen Vaccines & PreventionJanssen Vaccines & PreventionJanssen Vaccines & PreventionJanssen Vaccines & PreventionAbstract The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector–based vaccines significantly influences antigen-specific immune responses induced by a subsequent vaccination with Ad26 vector–based vaccine regimens against different disease targets in non-human primates. A homologous Ad26 vector–based vaccination regimen or heterologous regimens (Ad26/Ad35 or Ad26/Modified Vaccinia Ankara [MVA]) induced target pathogen–specific immunity in animals, but also persistent neutralizing antibodies and T-cell responses against the vectors. However, subsequent vaccination (interval, 26–57 weeks) with homologous and heterologous Ad26 vector–based vaccine regimens encoding different target pathogen immunogens did not reveal consistent differences in humoral or cellular immune responses against the target pathogen, as compared to responses in naïve animals. These results support the sequential use of Ad26 vector–based vaccine regimens targeting different diseases.https://doi.org/10.1038/s41541-022-00567-w |
| spellingShingle | Selina Khan Nadine C. Salisch Ana Izquierdo Gil Satish Boedhoe Karin Feddes-de Boer Jan Serroyen Hanneke Schuitemaker Roland C. Zahn Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets npj Vaccines |
| title | Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets |
| title_full | Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets |
| title_fullStr | Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets |
| title_full_unstemmed | Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets |
| title_short | Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets |
| title_sort | sequential use of ad26 based vaccine regimens in nhp to induce immunity against different disease targets |
| url | https://doi.org/10.1038/s41541-022-00567-w |
| work_keys_str_mv | AT selinakhan sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT nadinecsalisch sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT anaizquierdogil sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT satishboedhoe sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT karinfeddesdeboer sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT janserroyen sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT hannekeschuitemaker sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets AT rolandczahn sequentialuseofad26basedvaccineregimensinnhptoinduceimmunityagainstdifferentdiseasetargets |